WASHINGTON (Reuters) - Amgen Inc's drug from a high profile new class of experimental medicines lowered "bad" LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday.
via Reuters: Health News Read More Here..
No comments:
Post a Comment